FGF homologs and antibodies thereto

The present invention relates to antibodies and fragments thereof, polynucleotide and polypeptide molecules for zFGF5 a novel member of the FGF family. The polypeptides, and polynucleotides encoding them, are proliferative for muscle cells, in particular cardiac cells and may be used for remodeling cardiac tissue and improving cardiac function. The present invention also includes antibodies to the zFGF5 polypeptides.

Mutants of IL-29

Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.

Polynucleotide encoding an IL-28B polypeptide

Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.

Polynucleotide encoding an IL-29 polypeptide

Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.

FGF homolog polypeptides

The present invention relates to polynucleotide and polypeptide molecules for zFGF-5 a novel member of the FGF family. The polypeptides, and polynucleotides encoding them, are proliferative for muscle cells and may be used for remodelling cardiac tissue and improving cardiac function. The present invention also includes antibodies to the zFGF-5 polypeptides.

Homogeneous preparations of IL-28 and IL-29

Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.

Fibroblast growth factor homologs

Polynucleotide encoding an IL-28B polypeptide

Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.

FGF Homologs

The present invention relates to polynucleotide and polypeptide molecules for zFGF-5 a novel member of the FGF family. The polypeptides, and polynucleotides encoding them, are proliferative for muscle cells and may be used for remodelling cardiac tissue and improving cardiac function. The present invention also includes antibodies to the zFGF-5 polypeptides.

HOMOGENEOUS PREPARATIONS OF IL-28 AND IL-29

Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity. 1. A method of treating a patient having a hepatitis C virus infection comprising administering to the patient a therapeutically effective amount of a composition comprising a polypeptide that comprises an amino acid sequence having at least 97% sequence identity to SEQ ID NO: 159 , wherein in said amino acid sequence the amino acid residue that corresponds to position 166 of SEQ ID NO:159 is Ser , Ala , Thr , Val , or Asn , and wherein the polypeptide has anti-hepatitis C activity ,and a pharmaceutically acceptable vehicle,wherein after administration of the composition the hepatitis C infection is reduced.220.-. (canceled) The present application is a divisional of U.S. patent application Ser. No. 13/687,851, filed Nov. 28, 2012, which is a divisional of U.S. patent application Ser. No. 13/161,720, filed Jun. 16, 2011, now U.S. Pat. No. 8,343,476, which is a divisional of U.S. patent application Ser. No. 12/572,167, filed Oct. 1, 2009, now abandoned, which is a divisional of U.S. patent application Ser. No. 12/043,885, filed Mar. 6, 2008, now U.S. Pat. No. 7,727,518, which is a divisional of U.S. patent application Ser. No. 11/549,469, filed Oct. 13, 2006, now U.S. Pat. No. 7,468,423, which is a divisional of U.S. patent application Ser. No. 10/914,772, filed Aug. 9, 2004, now U.S. Pat. No. 7,157,559, which claims the benefit of U.S. Patent Application Nos. 60/493,194, filed Aug. 7, 2003, 60/551,841, filed Mar. 10, 2004, and 60/559,142, filed Apr. 2, 2004, all of which are herein incorporated by reference.Cytokines play important roles in the regulation of hematopoiesis and immune responses, and can ...

Mutants of IL-29

Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.

Polynucleotide encoding an IL-29 polypeptide

Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.

Homogeneous preparations of IL-28 and IL-29

Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.

Polynucleotide encoding an IL-28A polypeptide

Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.

Homogeneous preparations of IL-28 and IL-29

Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.

Polynucleotide encoding an IL-28B polypeptide

Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.

HOMOGENEOUS PREPARATIONS OF IL-31

Homogeneous preparations of human and murine IL-31 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. 1. An isolated polypeptide comprising amino acid residues 1-139 of SEQ ID NO:18.2. A formulation comprising the polypeptide of claim 1 , and a pharmaceutically acceptable vehicle.3. A kit comprising the formulation of . The present application is a continuation of U.S. patent application Ser. No. 14/476,866, filed Sep. 4, 2014, which is a continuation of U.S. patent application Ser. No. 13/094,959, filed Apr. 27, 2011, now abandoned, which is a continuation of U.S. patent application Ser. No. 12/478,185, filed Jun. 4, 2009, now abandoned, which is a continuation of U.S. patent application Ser. No. 11/344,451, filed Jan. 30, 2006, now abandoned, which claims the benefit of U.S. Provisional Application Ser. No. 60/648,189, filed Jan. 28, 2005, all of which is herein incorporated by reference.The increased availability and identification of genes from human and other genomes has led to an increased need for efficient expression and purification of recombinant proteins. The expression of proteins in bacteria is by far the most widely used approach for the production of cloned genes. For many reasons, expression in bacteria is preferred to expression in eukaryotic cells. For example, bacteria are much easier to grow than eukaryotic cells. More specifically, the availability of a wealth of sophisticated molecular genetic tools and thousands of mutants make , as an expression host, extremely useful for protein production. However, the high-level production of functional proteins in , especially those from eukaryotic sources has often been difficult.IL-31 is a recently discovered protein having the structure of a four-helical-bundle cytokine. This new cytokine is fully described in ...

Homogeneous preparations of IL-28A mutants

Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.

Polynucleotide encoding an IL-28A polypepide

Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.

FGF homologs

The present invention relates to polynucleotide and polypeptide molecules for zFGF5 a novel member of the FGF family. The polypeptides, and polynucleotides encoding them, are proliferative for muscle cells, in particular cardiac cells and may be used for remodeling cardiac tissue and improving cardiac function. The present invention also includes antibodies to the zFGF5 polypeptides.

Polynucleotide encoding an il-29 polypeptide

Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.

Method of using IL-29 cysteine mutant to treat hepatitis C and hepatitis B

Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.

Homogeneous preparations of IL-28 A

Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.

Homogeneous preparations of IL-28 and IL-29

Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.

HOMOGENEOUS PREPARATIONS OF IL-28 AND IL-29

Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity. 1. An isolated polypeptide comprising an amino acid sequence having at least 96% sequence identity to SEQ ID NO:159 , wherein the polypeptide has anti-hepatitis B and/or C activity.2. The polypeptide of claim 1 , wherein the polypeptide comprises an amino acid sequence having at least 97% sequence identity to SEQ ID NO:159.3. The polypeptide of claim 1 , wherein the polypeptide comprises an amino acid sequence having at least 98% sequence identity to SEQ ID NO:159.4. The polypeptide of claim 1 , wherein the polypeptide comprises an amino acid sequence having at least 99% sequence identity to SEQ ID NO:159.5. The polypeptide of claim 1 , wherein the polypeptide comprises an amino acid sequence of SEQ ID NO:159 claim 1 , wherein the residue at position 166 is a Serine.6. The polypeptide of wherein the polypeptide further comprises a polyethylene glycol moiety covalently attached N-terminally to the polypeptide.7. The polypeptide of wherein the polyethylene glycol moiety is mPEG propionaldehyde.8. The polypeptide of wherein the mPEG propionaldehyde has a molecular weight of about 20 kD.9. The polypeptide of wherein the mPEG propionaldehyde is linear.10. A fusion protein comprising a polypeptide that comprises an amino acid sequence having at least 96% sequence identity to SEQ ID NO:159 and a polyalkyl oxide moiety claim 7 , wherein the polypeptide has anti-hepatitis B and/or C activity.11. The fusion protein of wherein the polyalkyl oxide moiety is polyethylene glycol.12. The fusion protein of wherein the polyethylene glycol is mPEG propionaldehyde.13. The fusion protein of wherein the polyethylene glycol ...

Homogeneous preparations of IL-28 and IL-29

Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.

Polynucleotide encoding an IL-28A polypeptide

Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.

Homogeneous preparations of IL-28A cysteine mutants

Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.

HOMOGENEOUS PREPARATIONS OF IL-28 AND IL-29

Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.

Homogeneous preparations of IL-28 and IL-29

Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.

Homogeneous preparations of IL-28A cysteine mutants

Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.

Polynucleotide encoding an IL-28B polypeptide

Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.

Polynucleotide encoding an IL-28A polypeptide

Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.

HOMOGENEOUS PREPARATIONS OF IL-28 AND IL-29

Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.

HOMOGENEOUS PREPARATIONS OF IL-31

Homogeneous preparations of human and murine IL-31 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. 1. An isolated polypeptide comprising amino acid residues 1-139 of SEQ ID NO:18.2. A formulation comprising the polypeptide of claim 1 , and a pharmaceutically acceptable vehicle.3. A kit comprising the formulation of . The present application is a continuation of U.S. patent application Ser. No. 15/213,717, filed Jul. 19, 2016, which is a continuation of U.S. patent application Ser. No. 14/476,866, filed Sep. 4, 2014, now abandoned, which is a continuation of U.S. patent application Ser. No. 13/094,959, filed Apr. 27, 2011, now abandoned, which is a continuation of U.S. patent application Ser. No. 12/478,185, filed Jun. 4, 2009, now abandoned, which is a continuation of U.S. patent application Ser. No. 11/344,451, filed Jan. 30, 2006, now abandoned, which claims the benefit of U.S. Provisional Application Ser. No. 60/648,189, filed Jan. 28, 2005, all of which is herein incorporated by reference.The increased availability and identification of genes from human and other genomes has led to an increased need for efficient expression and purification of recombinant proteins. The expression of proteins in bacteria is by far the most widely used approach for the production of cloned genes. For many reasons, expression in bacteria is preferred to expression in eukaryotic cells. For example, bacteria are much easier to grow than eukaryotic cells. More specifically, the availability of a wealth of sophisticated molecular genetic tools and thousands of mutants make , as an expression host, extremely useful for protein production. However, the high-level production of functional proteins in ., especially those from eukaryotic sources has often been difficult.IL-31 is a recently ...

HOMOGENOUS PREPARATIONS OF IL-28 AND IL-29

Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity. 1. A method of treating a patient having a hepatitis C virus infection comprising administering to the patient a therapeutically effective amount of a composition comprising a polypeptide that comprises an amino acid sequence having at least 97% sequence identity to SEQ ID NO:159 , wherein in said amino acid sequence the amino acid residue that corresponds to position 166 of SEQ ID NO:159 is Ser , Ala , Thr , Val , or Asn , and wherein the polypeptide has anti-hepatitis C activity ,and a pharmaceutically acceptable vehicle,wherein after administration of the composition the hepatitis C infection is reduced.3. The method of claim 1 , wherein the polypeptide comprises an amino acid sequence having at least 98% sequence identity to SEQ ID NO:159.4. The method of claim 1 , wherein the polypeptide comprises an amino acid sequence having at least 99% sequence identity to SEQ ID NO:159.5. The method of claim 1 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:159 claim 1 , wherein the residue at position 166 is a Serine.6. The method of wherein the polypeptide further comprises a polyethylene glycol moiety covalently attached N-terminally to the polypeptide.7. The method of wherein the polyethylene glycol moiety is mPEG propionaldehyde.8. The method of wherein the mPEG propionaldehyde has a molecular weight of about 20 kD.9. The method of wherein the mPEG propionaldehyde is linear.10. A method of treating a patient having a hepatitis C virus infection comprising administering to the patient a therapeutically effective amount of a composition comprising a fusion protein comprising a ...

Homogeneous preparations of IL-28

Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.

HOMOGENEOUS PREPARATIONS OF IL-31

Homogeneous preparations of human and murine IL-31 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. 1. An isolated polypeptide comprising amino acid residues 1-139 of SEQ ID NO:18.2. A formulation comprising the polypeptide of claim 1 , and a pharmaceutically acceptable vehicle.3. A kit comprising the formulation of . The present application is a continuation of U.S. patent application Ser. No. 15/382,107, filed Dec. 16, 2016, which is a continuation of U.S. patent application Ser. No. 15/213,717, filed Jul. 19, 2016, which is a continuation of U.S. patent application Ser. No. 14/476,866, filed Sep. 4, 2014, now abandoned, which is a continuation of U.S. patent application Ser. No. 13/094,959, filed Apr. 27, 2011, now abandoned, which is a continuation of U.S. patent application Ser. No. 12/478,185, filed Jun. 4, 2009, now abandoned, which is a continuation of U.S. patent application Ser. No. 11/344,451, filed Jan. 30, 2006, now abandoned, which claims the benefit of U.S. Provisional Application Ser. No. 60/648,189, filed Jan. 28, 2005, all of which is herein incorporated by reference.The increased availability and identification of genes from human and other genomes has led to an increased need for efficient expression and purification of recombinant proteins. The expression of proteins in bacteria is by far the most widely used approach for the production of cloned genes. For many reasons, expression in bacteria is preferred to expression in eukaryotic cells. For example, bacteria are much easier to grow than eukaryotic cells. More specifically, the availability of a wealth of sophisticated molecular genetic tools and thousands of mutants make , as an expression host, extremely useful for protein production. However, the high-level production of functional proteins in , ...

NOVEL FGF HOMOLOGS

The present invention relates to polynucleotide and polypeptide molecules for zFGF5 a novel member of the FGF family. The polypeptides, and polynucleotides encoding them, are proliferative for muscle cells, in particular cardiac cells and may be used for remodeling cardiac tissue and improving cardiac function. The present invention also includes antibodies to the zFGF5 polypeptides.

Homogenous preparations of il-28 and il-29

Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.

HOMOGENEOUS PREPARATIONS OF IL-31

Homogeneous preparations of human and murine IL-31 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. 1. An isolated polypeptide comprising amino acid residues 1-139 of SEQ ID NO:18.2. A formulation comprising the polypeptide of claim 1 , and a pharmaceutically acceptable vehicle.3. A kit comprising the formulation of . The present application is a continuation of U.S. patent application Ser. No. 12/478,185, filed Jun. 4, 2009, which is a continuation of U.S. patent application Ser. No. 11/344,451, filed Jan. 30, 2006, now abandoned, which claims the benefit of U.S. Provisional Application Ser. No. 60/648,189, filed Jan. 28, 2005, all of which is herein incorporated by reference.The increased availability and identification of genes from human and other genomes has led to an increased need for efficient expression and purification of recombinant proteins. The expression of proteins in bacteria is by far the most widely used approach for the production of cloned genes. For many reasons, expression in bacteria is preferred to expression in eukaryotic cells. For example, bacteria are much easier to grow than eukaryotic cells. More specifically, the availability of a wealth of sophisticated molecular genetic tools and thousands of mutants make , as an expression host, extremely useful for protein production. However, the high-level production of functional proteins in ., especially those from eukaryotic sources has often been difficult.IL-31 is a recently discovered protein having the structure of a four-helical-bundle cytokine. This new cytokine is fully described in co-owned PCT application W0 03/060090 and Dillon, et al., 5:752-760, 2004; both incorporated by reference herein. IL-31 is a ligand with high specificity for the receptor IL-31RA and at least one additional subunit ...

HOMOGENEOUS PREPARATIONS OF IL-31

Homogeneous preparations of human and murine IL-31 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. 1. An isolated polypeptide comprising amino acid residues 1-139 of SEQ ID NO:18.2. A formulation comprising the polypeptide of claim 1 , and a pharmaceutically acceptable vehicle.3. A kit comprising the formulation of . The present application is a continuation of U.S. patent application Ser. No. 13/094,959, filed Apr. 27, 2011, which is a continuation of U.S. patent application Ser. No. 12/478,185, filed Jun. 4, 2009, now abandoned, which is a continuation of U.S. patent application Ser. No. 11/344,451, filed Jan. 30, 2006, now abandoned, which claims the benefit of U.S. Provisional Application Ser. No. 60/648,189, filed Jan. 28, 2005, all of which is herein incorporated by reference.The increased availability and identification of genes from human and other genomes has led to an increased need for efficient expression and purification of recombinant proteins. The expression of proteins in bacteria is by far the most widely used approach for the production of cloned genes. For many reasons, expression in bacteria is preferred to expression in eukaryotic cells. For example, bacteria are much easier to grow than eukaryotic cells. More specifically, the availability of a wealth of sophisticated molecular genetic tools and thousands of mutants make , as an expression host, extremely useful for protein production. However, the high-level production of functional proteins in , especially those from eukaryotic sources has often been difficult.IL-31 is a recently discovered protein having the structure of a four-helical-bundle cytokine. This new cytokine is fully described in co-owned PCT application WO 03/060090 and Dillon, et al., 5:752-760, 2004; both incorporated by reference ...

HOMOGENEOUS PREPARATIONS OF IL-29

Homogeneous preparations of IL-28 and IL-29

There is provided an isolated polypeptide comprising an amino acid sequence having at least 90% sequence identity to amino acid residues 1-181 of SEQ ID NO:4; wherein the amino acid residue that corresponds to the cysteine at position 15 of SEQ ID NO:4 is substituted with another amino acid; wherein the amino acid residues that correspond to the cysteine at position 49 and position 145 of SEQ ID NO:4 form a first disulfide bond, and wherein the amino acid residues that correspond to the cysteine at position 112 and position 171 of SEQ ID NO:4 form a second disulfide bond; and wherein the polypeptide induces the expression of Interferon Stimulated Genes in human hepatocytes.

Homogeneous preparations of IL-28 and IL-29

There is provided an isolated polypeptide comprising an amino acid sequence having at least 90% sequence identity to amino acid residues 1-181 of SEQ ID NO:4; wherein the amino acid residue that corresponds to the cysteine at position 171 of SEQ ID NO:4 is substituted with another amino acid; wherein the amino acid residues that correspond to the cysteine at position 15 and position 112 of SEQ ID NO:4 form a first disulfide bond, and wherein the amino acid residues that correspond to the cysteine at position 49 and position 145 of SEQ ID NO:4 form a second disulfide bond; and wherein the polypeptide induces the expression of Interferon Stimulated Genes in human hepatocytes.

Method of using IL-29 cystehne mutant to treat hepatitis C and hepatitis B

Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.

Homogeneous preparations of il-28 and il-29

Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.

Homogeneous preparations of IL-31

Homogeneous preparations of human and murine IL-31 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity.

Homogeneous preparations of IL-29

Homogeneous preparations of il-31

Homogeneous preparations of human and murine IL-31 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity.

HOMOGENEOUS PREPARATIONS OF IL-29

Production of GAD65 in methylotrophic yeast

Methylotrophic yeast are used for high-level expression of GAD65 that makes the production of GAD65 feasible on an industrial scale. A methanol-inducible promoter from, for example, an alcohol oxidase gene, such as Pichia pastoris AOX1, can be used to regulate GAD65 expression. The recombinant GAD65 has high specific activity and retains antigenic characteristics of the native molecule that are essential to immunological assays and therapeutic protocols.

expression vector, transformed or transfected yeast or bacterial cell, process for producing a fgf homologous polypeptide, pharmaceutical composition, and processes for stimulating ex vivo myocyte or myocyte progenitor cells

Homogeneous preparations of il-29

Homogeneous preparations of il-28 and il-29

Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.

Homogeneous preparations of il-28 and il-29

Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.

Homogeneous preparations of il-28 and il-29

Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.

Fibroblast growth factor homologs

There is provided an isolated polynucleotide molecule encoding a fibroblast growth factor (FGF) homolog polypeptide comprising a nucleotide sequence as shown in SEQ ID. NO:1 from nucleotide 82 to nucleotide 621; an isolated polynucleotide molecule encoding a fibroblast growth factor (FGF) homolog polypeptide comprising a nucleotide sequence as shown in SEQ ID. NO:6 from nucleotide 82 to nucleotide 621I; an isolated polynucleotide molecule encoding a fibroblast growth factor (FGF) homolog polypeptide comprising a nucleotide sequence that encodes a polypeptide of SEQ ID. NO:2 from amino acid residue 28 to residue 196; and an isolated polynucleotide molecule encoding a fibroblast growth factor (FGF) homolog polypeptide comprising a nucleotide sequence that encodes a polypeptide of SEQ ID. NO:2 from amino acid residue 28 to residue 207.

Novel fgf homologs

The present invention relates to polynucleotide and polypeptide molecules for zFGF-5, a novel member of the FGF family. The polypeptides, and polynucleotides encoding them, are proliferative for muscle cells and may be used for remodelling cardiac tissue and improving cardiac function. The present invention also includes antibodies to the zFGF-5 polypeptides.

Fibroblasten-wachstumsfaktoren homologefibroblasten-wachstumsfaktoren homologe

Fibroblasten-wachstumsfaktoren-homologe